Literature DB >> 26873297

Neuroendocrine tumor of the common bile duct.

Kiyotaka Hosoda1, Akira Kobayashi2, Akira Shimizu1, Noriyuki Kitagawa1, Tetsuya Ito3, Akira Yamada4, Shin-Ichi Miyagawa1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26873297     DOI： 10.1016/j.surg.2016.01.001

Source DB:  PubMed          Journal:  Surgery        ISSN： 0039-6060            Impact factor:   3.982


× No keyword cloud information.
  6 in total

1.  Primary extrahepatic bile duct neuroendocrine tumor with obstructive jaundice masquerading as a Klatskin tumor.

Authors:  Lauren Hoepfner; Jared A White
Journal:  J Surg Case Rep       Date:  2017-06-05

2.  Neuroendocrine tumor of the common bile duct: a case report and review of the literature.

Authors:  Zhong Liu; Deng-Yong Zhang; Zheng Lu; Pei Zhang; Wan-Liang Sun; Xiang Ma; Hua Wu; Bin-Quan Wu; Shuo Zhou
Journal:  Onco Targets Ther       Date:  2018-04-23       Impact factor: 4.147

3.  Mixed adenoneuroendocrine carcinoma of the extrahepatic bile duct: a case report.

Authors:  Hai-Wen Zhang; Kai Kou; Jun Qi; En-Bo Xie; Meng Wang; Yan Li; Guo-Yue Lv; Guang-Yi Wang
Journal:  J Int Med Res       Date:  2019-06-03       Impact factor: 1.671

4.  Mixed adenoendocrine carcinoma in the extrahepatic biliary tract: A case report and literature review.

Authors:  Liang Zhang; Zhengtao Yang; Qing Chen; Mengxia Li; Xiaolu Zhu; Dalong Wan; Haiyang Xie; Shusen Zheng
Journal:  Oncol Lett       Date:  2019-06-20       Impact factor: 2.967

5.  Challenges in treatment of a patient suffering from neuroendocrine tumor G1 of the hilar bile duct: a case report.

Authors:  Biao Zhang; Shuang Li; Zhen Sun; Xu Chen; Bing Qi; Qingkai Zhang; Guixin Zhang; Dong Shang
Journal:  BMC Gastroenterol       Date:  2022-01-08       Impact factor: 3.067

6.  Biliary Neuroendocrine Neoplasms: Analysis of Prognostic Factors and Development and Validation of a Nomogram.

Authors:  Shengnan Zhou; Shitao Jiang; Weijie Chen; Haixin Yin; Liangbo Dong; Hao Zhao; Shaoqi Han; Xiaodong He
Journal:  Front Oncol       Date:  2021-07-19       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.